Immunic is trading 5.42% up at $13.43 ahead of its scheduled September 9, 2026 virtual R&D Day.
- The event will discuss relapsing multiple sclerosis and lead asset vidofludimus calcium.
- Management and external MS specialists will participate from 11:00 a.m. to 12:30 p.m. ET.
- No new clinical results, regulatory approval, or earnings announcement was reported; Phase 3 ENSURE data remain expected by year-end.